CA2049342A1 - Formules pour stabiliser les anticorps igm - Google Patents

Formules pour stabiliser les anticorps igm

Info

Publication number: CA2049342A1
Authority: CA; Canada
Prior art keywords: composition; igm; sodium; lyophilized; igm antibodies
Prior art date: 1989-03-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2049342

Other languages

English (en)

Inventor

Sally Bolmer

Jeffrey A. Mattis

Christopher P. Phillips

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Biotech Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-03-27

Filing date

1990-03-13

Publication date

1990-09-28

1990-03-13 Application filed by Individual filed Critical Individual

1990-09-28 Publication of CA2049342A1 publication Critical patent/CA2049342A1/fr

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 73
230000000087 stabilizing effect Effects 0.000 title abstract description 11
238000009472 formulation Methods 0.000 title description 29
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 49
102000008100 Human Serum Albumin Human genes 0.000 claims description 28
108091006905 Human Serum Albumin Proteins 0.000 claims description 28
239000011780 sodium chloride Substances 0.000 claims description 27
DZTHIGRZJZPRDV-UHFFFAOYSA-M N-acetyltryptophanate Chemical compound C1=CC=C2C(CC(NC(=O)C)C([O-])=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-M 0.000 claims description 20
102000004169 proteins and genes Human genes 0.000 claims description 19
108090000623 proteins and genes Proteins 0.000 claims description 19
229960005480 sodium caprylate Drugs 0.000 claims description 18
BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims description 18
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 15
229960000281 trometamol Drugs 0.000 claims description 14
239000000872 buffer Substances 0.000 claims description 12
108060003951 Immunoglobulin Proteins 0.000 claims description 9
102000018358 immunoglobulin Human genes 0.000 claims description 9
239000000843 powder Substances 0.000 claims description 9
239000001488 sodium phosphate Substances 0.000 claims description 7
229910000162 sodium phosphate Inorganic materials 0.000 claims description 7
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 7
239000008363 phosphate buffer Substances 0.000 claims description 5
229910019142 PO4 Inorganic materials 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
239000010452 phosphate Substances 0.000 claims description 2
229940102223 injectable solution Drugs 0.000 claims 5
239000007972 injectable composition Substances 0.000 claims 4
239000000047 product Substances 0.000 abstract description 25
239000000243 solution Substances 0.000 abstract description 24
230000015572 biosynthetic process Effects 0.000 abstract description 6
239000007853 buffer solution Substances 0.000 abstract description 4
239000012467 final product Substances 0.000 abstract description 2
238000002347 injection Methods 0.000 abstract description 2
239000007924 injection Substances 0.000 abstract description 2
230000002401 inhibitory effect Effects 0.000 abstract 1
238000001556 precipitation Methods 0.000 abstract 1
239000000902 placebo Substances 0.000 description 14
229940068196 placebo Drugs 0.000 description 13
239000007788 liquid Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
238000002360 preparation method Methods 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
238000004108 freeze drying Methods 0.000 description 5
229940072221 immunoglobulins Drugs 0.000 description 5
239000000126 substance Substances 0.000 description 5
102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
230000000694 effects Effects 0.000 description 4
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 4
239000002245 particle Substances 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000002523 gelfiltration Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
229940027941 immunoglobulin g Drugs 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000012263 liquid product Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
230000001376 precipitating effect Effects 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000282412 Homo Species 0.000 description 1
241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
102100035115 Testin Human genes 0.000 description 1
101710070533 Testin Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003171 anti-complementary effect Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000005189 flocculation Methods 0.000 description 1
230000016615 flocculation Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000012931 lyophilized formulation Substances 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000004845 protein aggregation Effects 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
239000000758 substrate Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-M tryptophanate Chemical compound C1=CC=C2C(CC(N)C([O-])=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-M 0.000 description 1
239000013026 undiluted sample Substances 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000012904 visual particle Substances 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Inorganic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA 2049342 1989-03-27 1990-03-13 Formules pour stabiliser les anticorps igm Abandoned CA2049342A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32857989A	1989-03-27	1989-03-27
US328,579		1989-03-27

Publications (1)

Publication Number	Publication Date
CA2049342A1 true CA2049342A1 (fr)	1990-09-28

Family

ID=23281559

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2049342 Abandoned CA2049342A1 (fr)	1989-03-27	1990-03-13	Formules pour stabiliser les anticorps igm

Country Status (4)

Country	Link
EP (1)	EP0465513A1 (fr)
JP (1)	JPH04504253A (fr)
CA (1)	CA2049342A1 (fr)
WO (1)	WO1990011091A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992000763A1 (fr) *	1990-07-03	1992-01-23	Akzo N.V.	Compose immunoreactif
JPH0565233A (ja) *	1991-03-08	1993-03-19	Mitsui Toatsu Chem Inc	モノクローナル抗体含有凍結乾燥製剤
EP0562125A4 (fr) *	1991-10-11	1994-03-18	Toray Industries	Composition a base d'anticorps.
EP0621774B1 (fr) *	1992-01-21	1996-12-18	Sri International	Procede ameliore de preparation de medicaments polypeptides sous forme de poudre
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
US6991790B1 (en)	1997-06-13	2006-01-31	Genentech, Inc.	Antibody formulation
AU2444899A (en) *	1998-01-22	1999-08-09	Astrazeneca Ab	Pharmaceutical formulation comprising an antibody and a citrate buffer
AU2002213441B2 (en)	2000-10-12	2006-10-26	Genentech, Inc.	Reduced-viscosity concentrated protein formulations
US8703126B2 (en)	2000-10-12	2014-04-22	Genentech, Inc.	Reduced-viscosity concentrated protein formulations
EP1428537B1 (fr) *	2001-08-29	2008-11-19	Chugai Seiyaku Kabushiki Kaisha	Preparations stabilisees contenant un anticorps
JP5290489B2 (ja)	2001-11-08	2013-09-18	アッヴィ・バイオセラピューティクス・インコーポレイテッド	Ｉｇｇ抗体の安定な液体医薬製剤
US20040033228A1 (en)	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
CN1798575A (zh)	2003-04-04	2006-07-05	健泰科生物技术公司	高浓度抗体和蛋白制剂
JP5322405B2 (ja) *	2007-06-07	2013-10-23	小林製薬株式会社	タンパク質含有組成物
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
AR076640A1 (es)	2009-03-06	2011-06-29	Genentech Inc	Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
HUE047173T2 (hu)	2010-03-01	2020-04-28	Bayer Healthcare Llc	Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
KR102167261B1 (ko)	2010-06-18	2020-10-20	엑스바이오테크, 인크.	관절염 치료
US10294296B2 (en)	2010-08-23	2019-05-21	Xbiotech, Inc.	Treatment for neoplastic diseases
PT2707030T (pt)	2011-05-09	2020-05-22	Mayo Found Medical Education & Res	Tratamentos de cancro
JP6247210B2 (ja) *	2011-07-05	2017-12-13	アルブミディクスアクティーゼルスカブ	アルブミン製剤及び用途
ES2695102T3 (es)	2011-09-23	2019-01-02	Xbiotech Inc	Tratamiento para la caquexia
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
US10413606B2 (en)	2012-10-01	2019-09-17	Mayo Foundation For Medical Education And Research	Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
US20160250351A1 (en)	2014-06-13	2016-09-01	Mayo Foundation For Medical Education And Research	Treating Lymphomas
EP3834889A1 (fr)	2014-06-16	2021-06-16	Mayo Foundation for Medical Education and Research	Traitement de myélomes
DK3204413T3 (da) *	2014-10-06	2019-12-09	Mayo Found Medical Education & Res	Bærerantistofsammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
US9446148B2 (en)	2014-10-06	2016-09-20	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh)	2015-08-18	2017-03-01	美國馬友醫藥教育研究基金會	載體－抗體組合物及其製造及使用方法
JP6921802B2 (ja) *	2015-08-18	2021-08-18	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチＭａｙｏＦｏｕｎｄａｔｉｏｎＦｏｒＭｅｄｉｃａｌＥｄｕｃａｔｉｏｎＡｎｄＲｅｓｅａｒｃｈ	キャリア結合剤組成物およびそれを作製および使用する方法
TW201713360A (en)	2015-10-06	2017-04-16	Mayo Foundation	Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (fr)	2016-01-07	2017-07-13	Mayo Foundation For Medical Education And Research	Procédés de traitement du cancer par interféron
WO2017139698A1 (fr)	2016-02-12	2017-08-17	Mayo Foundation For Medical Education And Research	Traitements des cancers hématologiques
EP3432928A4 (fr)	2016-03-21	2019-11-20	Mayo Foundation for Medical Education and Research	Procédés d'amélioration de l'indice thérapeutique d'un médicament chimiothérapeutique
US11305020B2 (en)	2016-03-21	2022-04-19	Mayo Foundation For Medical Education And Research	Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en)	2016-04-06	2020-04-14	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
CN109890419A (zh)	2016-09-01	2019-06-14	梅约医学教育与研究基金会	用于治疗癌症的载体-pd-l1结合剂组合物
CA3035377A1 (fr)	2016-09-01	2018-03-08	Mayo Foundation For Medical Education And Research	Compositions de nanoparticules pour cibler les cancers des lymphocytes t
WO2018048816A1 (fr)	2016-09-06	2018-03-15	Mayo Foundation For Medical Education And Research	Procédés de traitement du cancer exprimant pd-l1
US11590098B2 (en)	2016-09-06	2023-02-28	Mayo Foundation For Medical Education And Research	Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
EP3509643A1 (fr)	2016-09-06	2019-07-17	Mayo Foundation for Medical Education and Research	Compositions d'agents de liaison, de paclitaxel et d'albumine et leurs procédés d'utilisation et de production

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1546177A (en) *	1976-11-19	1979-05-16	Biokema Sa	Process for the preparation of a stable injectable solution
JPS5822085B2 (ja) *	1977-07-19	1983-05-06	株式会社ミドリ十字	静注用ガンマ・グロブリン製剤
ATE82136T1 (de) *	1987-08-10	1992-11-15	Miles Inc	Gereinigtes igm.

1990
- 1990-03-13 EP EP19900905158 patent/EP0465513A1/fr not_active Withdrawn
- 1990-03-13 WO PCT/US1990/001383 patent/WO1990011091A1/fr not_active Ceased
- 1990-03-13 JP JP2505100A patent/JPH04504253A/ja active Pending
- 1990-03-13 CA CA 2049342 patent/CA2049342A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
JPH04504253A (ja)	1992-07-30
WO1990011091A1 (fr)	1990-10-04
EP0465513A1 (fr)	1992-01-15

Legal Events

Date	Code	Title	Description
1998-03-13	FZDE	Dead

Publication	Publication Date	Title
CA2049342A1 (fr)	1990-09-28	Formules pour stabiliser les anticorps igm
Sarciaux et al.	1999	Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying
EP0417193B1 (fr)	1993-08-04	Preparation lyophilisee pour la stabilisation de produits a base d'anticorps
US12514925B2 (en)	2026-01-06	Room temperature stable lyophilized protein
Kerwin et al.	1998	Effects of tween 80 and sucrose on acute short-term stability and long-term storage at− 20 C of a recombinant hemoglobin
AU695084B2 (en)	1998-08-06	Formulations for factor IX
US9463241B2 (en)	2016-10-11	Method for stabilising an immunoglobulin G composition in liquid form
AU600246B2 (en)	1990-08-09	Stabilised human tissue plasminogen activator compositions
US20100056765A1 (en)	2010-03-04	Formulations That Inhibit Protein Aggregation
EP0417191A1 (fr)	1991-03-20	Formule de reactifs contenant des anticorps.
BR112012012080B1 (pt)	2022-11-29	Formulações de histidina-trealose do anticorpo t1h
JPS6191131A (ja)	1986-05-09	医薬品の吸着防止方法および組成物
US8372798B2 (en)	2013-02-12	High-concentration protein formulations and method of manufacture
CA3162569A1 (fr)	2021-07-29	Formulation d'anticorps stable
AU676833B2 (en)	1997-03-27	Pharmaceutical compositions containing IL-6
KR20040018458A (ko)	2004-03-03	Ｃｅｔｕｘｉｍａｂ 및 폴리옥시에틸렌 소르비탄 지방산에스테르를 포함하는 액형 제제
JPH11502205A (ja)	1999-02-23	ｈＣＧ液体製剤
KR900004799B1 (ko)	1990-07-06	안정한 감마 인터페론 제제 및 이의 제조방법
KR20200143449A (ko)	2020-12-23	메글루민 염을 사용하여 단백질을 포함하는 제형을 안정화시키는 방법
KR880002037B1 (ko)	1988-10-13	인터페론 조성물 및 이의 제조방법
WO2021141789A1 (fr)	2021-07-15	Formulations stables de peptides anticancéreux
JP2005508992A (ja)	2005-04-07	凍結乾燥されたモノクローナル抗体組成物
JPH0137118B2 (fr)	1989-08-04
RU2136313C1 (ru)	1999-09-10	Стабилизирующий состав для получения референс-сывороток, содержащих igm-антитела
JPS6399022A (ja)	1988-04-30	静脈内投与に適したガンマ・グロプリン